CliffBio
biologic

ryoncil

remestemcel-L-rknd

Loss of exclusivityDecember 2036projected — 12-year biologic exclusivity estimate
CompanyMesoblast →View the full company profile on CliffBio

Drug detail

Brand nameryoncil
Active ingredientremestemcel-L-rknd
Strength6.68X10^CELL/ML
Dosage formSuspension
RouteIntravenous
ModalityBiologic
FDA approvalDecember 2024
Marketing statusRx

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

ryoncil patent cliff — loss of exclusivity December 2036 | CliffBio